← Leaderboards
Susan Dana Jones
Immurx Llc
$4,353,753
Attributed
$4,353,753
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2009–13$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$4,353,753 · 5
By mechanism
R44$2,639,017 · 1
R43$1,714,736 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Immunity”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmunityBaseImmuneProductionCellular ImmunityResponseClinicVaccinesClinical TrialsT-LymphocyteImmune ResponseAgonistImmune SystemTechnologyTnfrsf5 GeneCd8b1 GeneMelanomaTumorInjection Of Therapeutic AgentInnovationExpression VectorAdjuvantCostIn Vivo
Grant awards (9)
Preclinical Development of a Novel and Powerful Immunotherapeutic$864,478
R44 · FY2013 · AI · contact PI
Preclinical Development of a Novel and Powerful Immunotherapeutic$847,617
R44 · FY2012 · AI · contact PI
Safe and effective anti CD154 antibodies for therapeutic intervention$300,000
R43 · FY2012 · AI · contact PI
Preclinical Development of a Novel and Powerful Immunotherapeutic$926,922
R44 · FY2011 · AI · contact PI
VISTA: A Novel Therapeutic Target That Negatively Regulates Immunity$300,000
R43 · FY2011 · AI · contact PI
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine$237,514
R43 · FY2011 · AI · contact PI
Angiogenesis antagonist plus CD40-TLR agonist adjuvant combination vaccine$300,000
R43 · FY2010 · AI · contact PI
Potent Vaccine Adjuvant Therapeutic$277,222
R43 · FY2010 · AI · contact PI
Potent Vaccine Adjuvant Therapeutic$300,000
R43 · FY2009 · AI · contact PI